METABOLIC ACTIVATION OF A MUTAGEN, 2-AMINO-6-METHYLDIPYRIDO-[1,2-a:3',2'-d]IMIDAZOLE. IDENTIFICATION OF 2-HYDROXYAMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE AND ITS REACTION WITH DNA

Yuichi Hashimoto, Koichi Shudo, and Toshihiko Okamoto

Faculty of Pharmaceutical Sciences University of Tokyo, Hongo, Bunkyo-ku, Japan

Received December 18,1979

#### SUMMARY:

A potent mutagen, 2-amino-6-methyldipyrido[1,2-a:3',2'-d]-imidazole(Glu-P-1), isolated from pyrolysates of L-glutamic acid and casein, was metabolically activated and bound to DNA. An activated form was identified as 2-hydroxyamino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole(N-OH-Glu-P-I). Synthetic N-OH-Glu-P-I reacted with DNA only after 0-acetylation to give a modified DNA, which on hydrolysis gave 2-(C<sup>8</sup>-guanyl)amino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole(gua-Glu-P-I). The same adduct was isolated from DNA modified with Glu-P-I by microsomes in vitro, as reported earlier.

## INTRODUCTION:

2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole(Glu-P-1) is a potent mutagen isolated from pyrolysates of L-glutamic acid<sup>1)</sup> and casein.<sup>2)</sup> It shows mutagenic activity after microsomal activation, and binds to DNA only in the presence of microsomal protein.<sup>3)</sup> The major modified base was identified as 2-(C<sup>8</sup>-guanyl)amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (gua-Glu-P-1).<sup>3)</sup> This suggests that the activated form leading to the modified base is probably 2-hydroxyamino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole(N-OH-Glu-P-1), because N-OH-Glu-P-1 can be an electrophile and probably can attack the nucleophilic 8-position of guanine in DNA. The results in this paper indicate that N-OH-Glu-P-1 is a metabolically activated form of Glu-P-1


and that the major modification of DNA by N-OH-Glu-P-1 is identical to that by Glu-P-1 mediated by rat liver microsomes in vitro. A possible mechanism of enzymatic binding of Glu-P-1 is discussed.

#### MATERIALS AND METHODS:

Calf thymus DNA and NADPH were purchased from Sigma and Oriental Company, respectively. Rat liver microsomes were prepared from male Wistar rats(100-150g) treated with polychlorinated biphenyls as described previously.  $^{4}$ )

The microsomal metabolites of Glu-P-1 were obtained by in vitro incubation of a solution of Glu-P-1(HBr-salt, 0.3mg/ml) with rat liver microsomes(5mg protein/ml) and NADPH(1mg/ml) at 37°C for 10 min. For identification of N-OH-Glu-P-1, the incubation mixture was extracted with ethyl acetate and analysed by high performance liquid chromatography(HPLC, Fig. 1a). The stopped flow ultra-violet(UV) spectrum was obtained with a Shimadzu SPD-1 System, and compared with that of authentic material under the same conditions(Fig. 1b).

N-OH-Glu-P-1 was prepared from 2-nitro-6-methyldipyrido-[1,2-a:3',2'-d]imidazole, which was obtained by oxidation of Glu-P-1. The reagent used for oxidation contained 30%H202,  $CF_3COOH$ ,  $(CF_3CO)_2O$ ,  $CH_2Cl_2$ , and  $Mo(CO)_6$ . The reaction was performed at 0°C for 15 min. The mixture was extracted with CH2Cl2 after basification, and the product was separated by silica gel column chromatography, and recrystalized from ethyl acetate with a yield of about 80%. The structure was deduced by mass spectroscopy (M+228) and NMR, and from the IR- and UV-(max. at 290 and 380 nm) spectra. Anal. Calcd. for  $C_{11}H_8N_4O_2$ : C, 57.86; H, 3.51; N, 24.56. Found: C, 57.82; H, 3.49; N, 24.45. Reduction of 2-nitro-6-methyldipyrido[1,2-a:3',2'-d]imidazole was performed by treatment with aluminum amalgamate in tetrahydrofuran(THF) at  $0^{\circ}\text{C}$  for 5 min. The mixture was evaporated after filtration, and the residue was washed with  $\mathrm{CH_2Cl_2}$ , and recrystalized from  $\text{n-C}_6\text{H}_{14}$ ,  $\text{CH}_2\text{Cl}_2$ , and  $\text{CH}_3\text{OH}$ . The yield was approximately 40%. The structure of the compound was deduced by mass spectroscopy (M<sup>+</sup>214) and NMR, and from the UV-spectrum(max. at 253, 300, 312, and 364 nm). Anal. Calcd. for  $C_{11}H_{10}N_4O$ : C, 61.68; H, 4.71;



Column: Zorbax SIL 4.6ø x 250 mm Solvent:  $CH_2Cl_2-CH_3CN-CH_3OH$  (75:20:5)

Flow rate: 1.0 ml/min

Detection: Absorbance at 254 nm


Fig. 1 (a) HPLC of microsomal metabolites of Glu-P-1; (b) UV spectra of peak-I and N-OH-Glu-P-1.

N, 26.16. Found: C, 61.96; H, 4.73; N, 25.99. Reaction of the compound with nitrosobenzene in the presence of acetic acid gave the azoxy derivative in good yield.

O-Acetylation of N-OH-Glu-P-1 was performed in THF at  $0^{\circ}$ C by bubbling with ketene gas. After most of the Glu-P-1 had disappeared, the excess ketene in solution was quenched with water. The solution was added directly to an aqueous solution of DNA without further work-up. Modified DNA was precipitated by addition of cold ethanol, and subjected to gel filtration chromatography(Sephadex G-25).

### RESULTS:

HPLC analysis of the mixture of Glu-P-1 metabolites indicated that the major metabolite of Glu-P-1 is N-OH-Glu-P-1 (Fig. 1). That is, peak-I was chromatographically identical



Peak-\*: Glu-P-1

Column: Plygosil  ${}_5C_{18}$ , 4.6ø x 150 mm Solvent:  ${}_{2}O$ -CH $_{3}OH$ -conc.NH $_{4}OH$  (59:40:1)

Flow rate: 1.0 ml/min

Detection: Absorbance at 254 nm

Fig. 2 HPLC of bases modified by Glu-P-1 in vitro (a) and by N-OH-Glu-P-1 after O-acetylation (b).

with that of authentic N-OH-Glu-P-1. The UV-spectrum of peak-I was also identical with that of N-OH-Glu-P-1(Fig. 1b). Under the conditions of incubation used, about 20% of the Glu-P-1 was metabolized to N-OH-Glu-P-1.

No significant binding of N-OH-Glu-P-1 to DNA was observed on incubation under neutral or slightly acidic conditions. However, after its O-acetylation with ketene, N-OH-Glu-P-1 bound to DNA. More than 1 mmoles/mol P(fluorometric estimation) of N-OH-Glu-P-1 bound to DNA, which is about 40 times the microsomesmediated binding of Glu-P-1 to DNA. When modified DNA was hydrolised enzymatically or with  $CF_3COOH$ , gua-Glu-P-1 was obtained as the major product. Gua-Glu-P-1 was identified by comparing

Scheme 1

its retention times on HPLC in several systems, and its fluorescence, excitation, and UV-spectra under acidic, neutral, and basic conditions with those of an authentic specimen synthesized as described previously. 3)

Fig. 2 shows the chromatographic patterns of bases modified by Glu-P-1 in vitro (a), and bases modified by N-OH-Glu-P-1 after its O-acetylation (b). The yield of gua-Glu-P-1, calculated from the amount of guanotides, was approximately 2% (UV spectroscopic measurement of peak-A(Fig. 2b)). Peak-C is the other common product, whose UV-spectrum is very similar to that of Glu-P-1. (No conjugative substitution on the Glu-P-1 skeleton seems to occur.)

### DISCUSSION:

The present results suggest a possible mechanism of binding of Glu-P-1 to DNA(Scheme 1). N-OH-Glu-P-1 is the major

metabolite of Glu-P-1, and binds to DNA after further activation. Consequently, N-OH-Glu-P-1 must be a proximate form of Glu-P-1 for reaction with DNA in vitro or in vivo. Though there is no evidence for biological O-acetylation of N-OH-Glu-P-1, O-esterification should be required for binding of N-OH-Glu-P-1 Recent studies have demonstrated that some carcinogenic to DNA. arylhydroxylamines react with nucleic acids after enzymatic phosphorylation or sulfonation in the presence of ATP or PAPS. $^{5)}$ In the case of 4-hydroxyaminoquinoline-N-oxide, the activation of the hydroxylamino group involves a characteristic amino acvlation. 6) The finding that O-acetylation is required for the binding is consistent with the postulated heterolytic cleavage of the N-O bond after O-acylation, O-phosphorylation, or Osulfonation and attack by the guanine moiety in DNA shown in Scheme 1.

# REFERENCES:

- 1) Yamamoto, T., Tsuji, K., Kosuge, T., Okamoto, T., Shudo, K., Takeda, K., Iitaka, Y., Yamaguchi, K., Seino, Y., Yahagi, T., and Sugimura, T. (1978) Proc. Japan Acad., 54, (B), 248-250.
- 2) Yamaguchi, K., Shudo, K., Okamoto, T., Zenda, H., Kosuge, T., and Sugimura, T. (1980) Gann, 000, 0000-0000.
- 3) Hashimoto, Y., Shudo, K., and Okamoto, T. (1979) Chem. Pharm. Bull. (Tokyo), 27, 2532-2534.
- 4) Hashimoto, Y., Takeda, K., Shudo, K., Okamoto, T., Sugimura, T., and Kosuge, T. (1978) Chem.-Biol. Interactions, 23, 137-140.
- 5) Miller, E. C., (1978) Cancer Research, 38, 1479-1496, and references therein.
- 6) Tada, M. and Tada, M. (1976) Nature, 225, 510-512.